Ralaniten triacetate
Modify Date: 2025-08-27 19:21:15
Ralaniten triacetate structure
|
Common Name | Ralaniten triacetate | ||
|---|---|---|---|---|
| CAS Number | 1637573-04-6 | Molecular Weight | 521.00 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C27H33ClO8 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Ralaniten triacetateRalaniten triacetate (EPI-506), the pro-drug of Ralaniten, is a first-in-class, orally active androgen receptor (AR) N-terminal domain (NTD) inhibitor. Ralaniten triacetate shows activity against both full length and resistance-related AR species, including AR-v7[1][2]. |
| Name | Ralaniten triacetate |
|---|
| Description | Ralaniten triacetate (EPI-506), the pro-drug of Ralaniten, is a first-in-class, orally active androgen receptor (AR) N-terminal domain (NTD) inhibitor. Ralaniten triacetate shows activity against both full length and resistance-related AR species, including AR-v7[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | Ralaniten triacetate (EPI-506) targets the N-terminal domain of the androgen receptor (AR), and is used for metastatic castration-resistant prostate cancer (mCRPC) research. EPI-506 is a first-in-class, highly-specific small molecule that binds to a novel target on the AR, the N-terminal domain (NTD) and directly inhibits AR transcriptional activity by blocking the interaction of the AR with transcriptional proteins[2]. |
| References |
| Molecular Formula | C27H33ClO8 |
|---|---|
| Molecular Weight | 521.00 |